Dokument: Health-Related Quality of Life in Multiple Myeloma Patients Treated with High- or Low-Dose Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation—Results from the LenaMain Trial (NCT00891384)

Titel:	Health-Related Quality of Life in Multiple Myeloma Patients Treated with High- or Low-Dose Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation—Results from the LenaMain Trial (NCT00891384)
URL für Lesezeichen:	https://docserv.uni-duesseldorf.de/servlets/DocumentServlet?id=67255
URN (NBN):	urn:nbn:de:hbz:061-20241029-113323-8
Kollektion:	Publikationen
Sprache:	Englisch
Dokumententyp:	Wissenschaftliche Texte » Artikel, Aufsatz
Medientyp:	Text
Autoren:	Boquoi, Amelie [Autor] Giagounidis, Aristoteles [Autor] Goldschmidt, Hartmut [Autor] Heinsch, Michael [Autor] Rummel, Mathias J. [Autor] Kröger, Nicolaus [Autor] Mai, Elias K. [Autor] Strapatsas, Judith [Autor] Haas, Rainer [Autor] Kobbe, Guido [Autor]
Dateien:	[Dateien anzeigen] Adobe PDF [Details] 2,06 MB in einer Datei [ZIP-Datei erzeugen] Dateien vom 29.10.2024 / geändert 29.10.2024
Stichwörter:	domain, lenalidomide, quality of life, maintenance, multiple myeloma, dosage
Beschreibung:	Simple Summary High-dose therapy with melphalan followed by autologous stem cell transplantation and lenalidomide maintenance has long been the standard of care for newly diagnosed patients with multiple myeloma. However, it is unclear how lenalidomide dosage or experienced side effects govern patients’ quality of life during long-term treatment. The LenaMain trial (NCT00891384) investigated lenalidomide maintenance at a high (25 mg) and a low dose (5 mg) and demonstrated that dosage had no impact on patients’ quality of life. Instead, high baseline scores for global health were maintained throughout the trial without difference between treatment arms which supports the feasibility of continuous lenalidomide treatment with a dose tailored to patients’ quality of life. Abstract Introduction: The LenaMain trial (NCT00891384) reported increased progression-free survival with 25 mg of lenalidomide maintenance compared to 5 mg. Here, we report the patient-reported outcomes. Materials and Methods: Scores obtained from the EORTC Quality of Life Questionnaire C30 were analyzed for longitudinal changes from baseline within the groups as well as cross-sectional scores. Results: Compliance rates were high, with 95.7% at baseline and 70% during maintenance. At study entry, scores were high for functioning and low for symptoms. During maintenance, the median global health status/quality of life (GHS/QoL) was constant, without significant differences over time (median GHS/QoL: 68 at baseline and 58 for Len high and 68 for Len low at 2 years) and between treatment arms (mean change < 2). Similarly, most functional scale domains were constant. Notably, diarrhea increased consistently for both treatment arms (baseline: −1.905 (range: −5.78–1.97); end of year 2: 16.071 (range: 5.72–26.42); p < 0.05). The subgroup analysis showed that neither disease activity, duration of treatment, nor adverse events affected the health-related quality of life (HR-QoL) or utility. Conclusion: High baseline scores were maintained throughout the trial without significant differences between the Len dosages, which supports continuous treatment with a dose tailored to patients’ HR-QoL.
Rechtliche Vermerke:	Originalveröffentlichung: Boquoi, A., Giagounidis, A., Goldschmidt, H., Heinsch, M., Rummel, M. J., Kröger, N., Mai, E. K., Strapatsas, J., Haas, R., & Kobbe, G. (2023). Health-Related Quality of Life in Multiple Myeloma Patients Treated with High- or Low-Dose Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation—Results from the LenaMain Trial (NCT00891384). Cancers, 15(21), Article 5157. https://doi.org/10.3390/cancers15215157
Lizenz:	Dieses Werk ist lizenziert unter einer Creative Commons Namensnennung 4.0 International Lizenz
Fachbereich / Einrichtung:	Medizinische Fakultät
Dokument erstellt am:	29.10.2024
Dateien geändert am:	29.10.2024